Rate My Professor Meg Musser

Musser's research focuses on clinically relevant veterinary oncology therapeutics, including high-dose ascorbate combined with chemotherapy for canine osteosarcoma, toceranib phosphate for feline pancreatic carcinoma and other tumors, prostaglandin EP4 receptor mRNA expression in various cancers, chemotherapy overdoses, and immunotherapy combinations such as doxorubicin with Immunocidin for canine splenic hemangiosarcoma. She has secured grants totaling over $345,000, including from the American Holistic Veterinary Medical Association ($22,172, 2020), Veterinary Cancer Society ($8,259, 2021), and Margaret B. Barry Foundation ($120,000, 2020). Key publications include "Response to tigilanol tiglate in dogs with mast cell tumors" (Journal of Veterinary Internal Medicine, October 2024), "Prognostic Impact of a Histologic Grading Scheme in Dogs Diagnosed With Rib Chondrosarcoma" (Veterinary and Comparative Oncology, November 2024), "Pilot safety evaluation of doxorubicin chemotherapy combined with non-specific immunotherapy (Immunocidin) for canine splenic hemangiosarcoma" (PLOS ONE, December 2022), and "Randomized trial evaluating chemotherapy alone or chemotherapy and a novel monoclonal antibody for canine T-cell lymphoma" (VetRecord Open, November 2022). Her teaching includes Veterinary Pharmacology and Therapeutics (BMS 7443), Small Animal Medicine Oncology Lectures (VCS 7444), Advanced Veterinary Oncology Elective (VCS 7318), and mentoring four current oncology residents. Musser collaborates with the University of Iowa's Holden Comprehensive Cancer Center Sarcoma Group.